The immune dysregulations in COVID-19: Implications for the management of rheumatic diseases

References

• Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020;324(8):782–93.
   PubMed Web of Science ®Google Scholar
• Raisi-Estabragh Z, McCracken C, Bethell MS, Cooper J, Cooper C, Caulfield MJ, et al. Greater risk of severe COVID-19 in Black, Asian and minority ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank. J Public Health (Oxf). 2020;42(3):451–60.
   PubMed Web of Science ®Google Scholar
• Khunti K, Singh AK, Pareek M, Hanif W. Is ethnicity linked to incidence or outcomes of covid-19? BMJ 2020;369:m1548.
   PubMed Web of Science ®Google Scholar
• Kopel J, Perisetti A, Roghani A, Aziz M, Gajendran M, Goyal H. Racial and gender-based differences in COVID-19. Front Public Health. 2020;8:418.
   PubMed Web of Science ®Google Scholar
• Hou Y, Zhao J, Martin W, Kallianpur A, Chung MK, Jehi L, et al. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. BMC Med. 2020;18(1):216.
   PubMed Web of Science ®Google Scholar
• Ortiz-Fernández L, Sawalha AH. Genetic variability in the expression of the SARS-CoV-2 host cell entry factors across populations. Genes Immun. 2020;21(4):269–72.
   PubMed Web of Science ®Google Scholar
• Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–43.
   PubMed Web of Science ®Google Scholar
• Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355–62.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. The Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–9.
   PubMed Web of Science ®Google Scholar
• Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J. Exp. Med 2020;217:e20200678.
   PubMed Web of Science ®Google Scholar
• Antony A, Connelly K, Silva TD, Eades L, Tillett W, Ayoub S, et al. Perspectives of patients with rheumatic diseases in the early phase of COVID-19. Arthritis Care Res (Hoboken). 2020;72(9):1189–95.
   PubMed Web of Science ®Google Scholar
• Lewandowski LB, Hsieh E. Global rheumatology in the time of COVID-19. Lancet Rheumatol. 2020;2(5):e254–5.
   PubMedGoogle Scholar
• Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–74.
   PubMed Web of Science ®Google Scholar
• Sterba G, Sterba Y, Iglesias GA. Macrophage activation syndrome in adults with rheumatic disease. Rev. Colomb. Reumatol. Engl. Ed 2016;23:137–43.
   Google Scholar
• Carter SJ, Tattersall RS, Ramanan AV. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford). 2019;58(1):5–17.
   PubMed Web of Science ®Google Scholar
• Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 2020;72(7):1059–63.
   PubMed Web of Science ®Google Scholar
• Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med 2020;26(6):842–4.
   PubMed Web of Science ®Google Scholar
• Wen W, Su W, Tang H, Le W, Zhang X, Zheng Y, et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov. 2020;6:41.
   PubMed Web of Science ®Google Scholar
• Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J. Exp. Med 2020;217:e20200652.
   PubMed Web of Science ®Google Scholar
• Schulze-Koops H. Lymphopenia and autoimmune diseases. Arthritis Res Ther. 2004;6(4):178–80.
   PubMed Web of Science ®Google Scholar
• Zheng H-Y, Zhang M, Yang C-X, Zhang N, Wang X-C, Yang X-P, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17(5):541–3.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl. Sci. Rev. 2020;7(6):998–1002.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–2.
   PubMed Web of Science ®Google Scholar
• Otsuka R, Seino K. Macrophage activation syndrome and COVID-19. Inflamm Regen. 2020;40(19):19.
   PubMedGoogle Scholar
• Ruscitti P, Bruno F, Berardicurti O, Acanfora C, Pavlych V, Palumbo P, et al. Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences. Ann Rheum Dis. 2020;79(9):1152–5.
   PubMed Web of Science ®Google Scholar
• Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity 2020;52(5):731–3.
   PubMed Web of Science ®Google Scholar
• Subbarao K, Mahanty S. Respiratory virus infections: understanding COVID-19. Immunity 2020;52(6):905–9.
   PubMed Web of Science ®Google Scholar
• Zhou R, To KK-W, Wong Y-C, Liu L, Zhou B, Li X, et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity 2020;53(4):864–77.e5.
   PubMed Web of Science ®Google Scholar
• Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–5.
   PubMed Web of Science ®Google Scholar
• Zhang J-Y, Wang X-M, Xing X, Xu Z, Zhang C, Song J-W, et al. Single-cell landscape of immunological responses in patients with COVID-19. Nat Immunol. 2020;21(9):1107–18.
   PubMed Web of Science ®Google Scholar
• Woodruff MC, Ramonell RP, Nguyen DC, Cashman KS, Saini AS, Haddad NS, et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat. Immunol 2020;21:1506–16.
   PubMed Web of Science ®Google Scholar
• Ma H, Zeng W, He H, Zhao D, Jiang D, Zhou P, et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol. 2020;17(7):773–5.
   PubMed Web of Science ®Google Scholar
• Ma K, Wang X, Shi X, Lin X, Xiao F, Ma X, et al. The expanding functional diversity of plasma cells in immunity and inflammation. Cell Mol Immunol. 2020;17(4):421–2.
   PubMed Web of Science ®Google Scholar
• Landewé RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR, Carmona L, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020;79(7):851–8.
   PubMed Web of Science ®Google Scholar
• Ye C, Cai S, Shen G, Guan H, Zhou L, Hu Y, et al. Clinical features of rheumatic patients infected with COVID-19 in Wuhan. Ann Rheum Dis. 2020;79(8):1007–13.
   PubMed Web of Science ®Google Scholar
• D’Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’. Ann. Rheum. Dis 2020;79:1156–62.
   PubMed Web of Science ®Google Scholar
• Zhong J, Shen G, Yang H, Huang A, Chen X, Dong L, et al. COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol 2020;2(9):e557–64.
   PubMedGoogle Scholar
• Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis. 2020;79(6):837–9.
   PubMed Web of Science ®Google Scholar
• Holubar J, Quintrec ML, Letaief H, Faillie JL, Pers Y-M, Jorgensen C. Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak. Ann Rheum Dis. 2020. DOI:10.1136/annrheumdis-2020-217919
   PubMedGoogle Scholar
• Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. 2020. DOI:10.1056/NEJMoa2021436
   Web of Science ®Google Scholar
• Gazzaruso C, Carlo Stella N, Mariani G, Tamburlini A, Garini P, Freddi E, et al. Impact of anti-rheumatic drugs and steroids on clinical course and prognosis of COVID-19. Clin Rheumatol. 2020;39(8):2475–7.
   PubMed Web of Science ®Google Scholar
• Ouédraogo D-D, Tiendrébéogo WJS, Kaboré F, Ntsiba H. COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments. Clin Rheumatol. 2020;39(7):2069–75.
   PubMed Web of Science ®Google Scholar
• Rinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I, Bar-Haim A, et al. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect. 2020;26(9):1259.e5–e7.
   Web of Science ®Google Scholar
• Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 1. Arthritis Rheumatol. 2020;72(8):1241–51.
   PubMed Web of Science ®Google Scholar
• Schett G, Sticherling M, Neurath MF. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol. 2020;20(5):271–2.
   PubMed Web of Science ®Google Scholar
• Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970–5.
   PubMed Web of Science ®Google Scholar
• Cavalli G, Luca GD, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2020;2(6):e325–31–e331.
   Google Scholar
• Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474–84–e484.
   Google Scholar
• Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16(6):335–45.
   PubMed Web of Science ®Google Scholar
• Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020;39(7):2085–94.
   PubMed Web of Science ®Google Scholar
• Le TT, Cramer JP, Chen R, Mayhew S. Evolution of the COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(10):667–8.
   PubMed Web of Science ®Google Scholar
• Meroni PL, Zavaglia D, Girmenia C. Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. Clin. Exp. Rheumatol 2018;36:317–28.
   PubMed Web of Science ®Google Scholar
• Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van AS, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39–52.
   PubMed Web of Science ®Google Scholar
• Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, China Medical Treatment Expert Group for Covid-19, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.
   PubMed Web of Science ®Google Scholar
• Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front. Immunol 2019;10:119. DOI:10.3389/fimmu.2019.00119
   PubMed Web of Science ®Google Scholar
• Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med. 2015;66:145–59.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13(4):289–98.
   PubMed Web of Science ®Google Scholar
• Schulert GS, Grom AA. Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol. 2014;28(2):277–92.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Monti S, Ingegnoli F, Balduzzi S, Caporali R, Montecucco C. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis Rheumatol. 2020;72(10):1600–6.
   PubMed Web of Science ®Google Scholar
• Michelena X, Borrell H, López-Corbeto M, López-Lasanta M, Moreno E, Pascual-Pastor M, et al. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2020;50(4):564–70.
   PubMed Web of Science ®Google Scholar
• Sanchez-Piedra C, Diaz-Torne C, Manero J, Pego-Reigosa JM, Rúa-Figueroa Í, Gonzalez-Gay MA, et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis. 2020;79(7):988–90.
   PubMed Web of Science ®Google Scholar
• Fredi M, Cavazzana I, Moschetti L, Andreoli L, Franceschini F, Airò P, et al. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study. Lancet Rheumatol 2020;2(9):e549–56–e556.
   Google Scholar
• Cho J, Kandane‐Rathnayake R, Louthrenoo W, Hoi A, Golder V, Chen Y-H, et al. COVID-19 infection in patients with systemic lupus erythematosus: data from the Asia Pacific Lupus collaboration. Int J Rheum Dis. 2020;23(9):1255–7.
   PubMed Web of Science ®Google Scholar
• Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020;79(5):667–8.
   PubMed Web of Science ®Google Scholar